Jacobs & Co. CA Has $1.20 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Jacobs & Co. CA trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 11,338 shares of the medical equipment provider’s stock after selling 2,429 shares during the period. Jacobs & Co. CA’s holdings in Zimmer Biomet were worth $1,197,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ZBH. Dunhill Financial LLC increased its holdings in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet during the third quarter worth $28,000. Bangor Savings Bank acquired a new position in Zimmer Biomet during the third quarter worth $31,000. Brooklyn Investment Group acquired a new position in Zimmer Biomet during the third quarter worth $35,000. Finally, Quarry LP acquired a new position in Zimmer Biomet during the second quarter worth $53,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

ZBH traded up $2.41 on Friday, hitting $103.95. 1,517,551 shares of the stock were exchanged, compared to its average volume of 1,565,623. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.67 and a 12 month high of $133.90. The business has a 50-day moving average of $108.09 and a two-hundred day moving average of $108.05. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The firm has a market capitalization of $20.69 billion, a price-to-earnings ratio of 19.76, a PEG ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter in the prior year, the business posted $1.65 earnings per share. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. BTIG Research reduced their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Evercore ISI reduced their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Royal Bank of Canada lifted their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th. Finally, Truist Financial lifted their price objective on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $123.33.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.